Biosimilars: what’s in a name?

Update on NSAIDs: risks and harms
The way a biosimilar is named may affect whether a pharmacist is willing to substitute it for a brand name biologic, a new study has found.The study, published in the Journal of Managed Care and Specialty Pharmacy, examined pharmacist perceptions of biosimilar naming conventions and their impact on confidence to dispense biosimilars.It also looked at

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous UK pharmacies selling e-cigarettes to minors
Next Paracetamol: largely ineffective and not exactly safe